Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
Status:
Terminated
Trial end date:
2018-12-29
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and
total-body irradiation before a donor bone marrow transplant helps stop the growth of
abnormal cells. It also helps stop the patient's immune system from rejecting the donor's
stem cells. When the healthy stem cells from a donor are infused into the patient they may
help the patient's bone marrow make stem cells, red blood cells, white blood cells, and
platelets. Sometimes the transplanted cells from a donor can make an immune response against
the body's normal cells. Giving sirolimus and mycophenolate mofetil after transplant may stop
this from happening.
PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide
together with total-body irradiation followed by a donor bone marrow transplant works in
treating patients with sickle cell anemia and other blood disorders.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins